Health
FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis
PHILADELPHIA, June 24, 2025--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stimulator (BlyS)-specific inhibiting monoclonal antibody, for subcutaneous injection in patients five years of age and older with active lupus nephritis (LN) who are receiving standard therapy. With this approval, GSK is expanding choices for belimumab treatment, offering pediatric lupus nephritis patien
About this update from Gsk Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/9430db6c8883b3566346ee31fd5b2446"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NQvd6XiCAzoL5xCkNzNn4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9430db6c8883b3566346ee31fd5b2446","width":480,"height":480}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration.","length":167,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":167,"olType":false},{"type":"text","content":"PHILADELPHIA, June 24, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stimulator (BlyS)-specific inhibiting monoclonal antibody, for subcutaneous injection in patients five years of age and older with active lupus nephritis (LN) who are receiving standard therapy. With this approval, GSK is expanding choices for belimumab treatment, offering pediatric lupus nephritis patients and caregivers a first-of-its-kind subcutaneous option that can be administered at home. The 200 mg/mL autoinjector was approved for pediatric patients with active systemic lupus erythematosus (SLE) in 2024.","length":727,"tagName":"p"},{"type":"text","content":"Lupus nephritis is one of the most serious complications of lupus and occurs when the immune system mistakenly attacks the kidneys, leading to inflammation and possibly to organ damage. About 30-50% of children with lupus develop LN, typically within one to two years after their initial lupus diagnosis.1,2","length":307,"tagName":"p"},{"type":"text","content":"Louise Vetter, President and Chief Executive Officer, Lupus Foundation of America said: "In children, lupus tends to be more aggressive and severe than it is in adults. The symptoms can be more intense, and the disease can have long-term effects on a child's growth and quality of life.1,2 Having the Benlysta autoinjector provides a much-needed option that can help reduce ...